Biswas S, Sumon M, Ahmed S, Ruma R, Parvin A, Paul D
Phage (New Rochelle). 2025; 5(4):186-202.
PMID: 40045940
PMC: 11876823.
DOI: 10.1089/phage.2024.0005.
Mursalin M, Coburn P, Longoria-Gonzalez L, Astley R, Fischetti V, Callegan M
Invest Ophthalmol Vis Sci. 2025; 66(1):39.
PMID: 39813055
PMC: 11741065.
DOI: 10.1167/iovs.66.1.39.
Mukherjee K, Moroz L
Front Cell Dev Biol. 2024; 12:1487920.
PMID: 39568508
PMC: 11576321.
DOI: 10.3389/fcell.2024.1487920.
Golban M, Charostad J, Kazemian H, Heidari H
Infect Dis Ther. 2024; 14(1):13-57.
PMID: 39549153
PMC: 11782739.
DOI: 10.1007/s40121-024-01069-z.
Zhydzetski A, Glowacka-Grzyb Z, Bukowski M, Zadlo T, Bonar E, Wladyka B
Molecules. 2024; 29(17).
PMID: 39274911
PMC: 11396672.
DOI: 10.3390/molecules29174065.
Discovery and characterization of a novel LysinB from F2 sub-cluster mycobacteriophage RitSun.
Arora R, Nadar K, Bajpai U
Sci Rep. 2024; 14(1):18073.
PMID: 39103410
PMC: 11300654.
DOI: 10.1038/s41598-024-68636-9.
Analyzing the impact of T7L variants overexpression on the metabolic profile of Escherichia coli.
Kairamkonda M, Saxena H, Gulati K, Poluri K
Metabolomics. 2024; 20(4):68.
PMID: 38941046
DOI: 10.1007/s11306-024-02133-y.
Effect of Domain Manipulation in the Staphylococcal Phage Endolysin, Endo88, on Lytic Efficiency and Host Range.
Krishnan M, Tham H, Wan Nur Ismah W, Yusoff K, Song A
Mol Biotechnol. 2024; .
PMID: 38904894
DOI: 10.1007/s12033-024-01216-4.
Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria.
Khan F, Rasheed F, Yang Y, Liu B, Zhang R
Front Pharmacol. 2024; 15:1385261.
PMID: 38831886
PMC: 11144922.
DOI: 10.3389/fphar.2024.1385261.
Antibiotic resistance and tolerance: What can drug delivery do against this global threat?.
Aparicio-Blanco J, Vishwakarma N, Lehr C, Prestidge C, Thomas N, Roberts R
Drug Deliv Transl Res. 2024; 14(6):1725-1734.
PMID: 38341386
PMC: 11052818.
DOI: 10.1007/s13346-023-01513-6.
Development of sensitizer peptide-fused endolysin Lys1S-L9P acting against multidrug-resistant gram-negative bacteria.
Son S, Kim J, Ryu S
Front Microbiol. 2023; 14:1296796.
PMID: 38075915
PMC: 10701683.
DOI: 10.3389/fmicb.2023.1296796.
Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens.
Karn S, Gangwar M, Kumar R, Bhartiya S, Nath G
Front Med (Lausanne). 2023; 10:1209782.
PMID: 37928478
PMC: 10620811.
DOI: 10.3389/fmed.2023.1209782.
An endolysin gene from Liberibacter asiaticus confers dual resistance to huanglongbing and citrus canker.
Xu L, Mo K, Ran D, Ma J, Zhang L, Sun Y
Hortic Res. 2023; 10(9):uhad159.
PMID: 37719271
PMC: 10500150.
DOI: 10.1093/hr/uhad159.
Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis.
Stevens R, Zhang H, Kajsik M, Ploski R, Rydzanicz M, Sabaka P
Front Med (Lausanne). 2023; 10:1238147.
PMID: 37649979
PMC: 10462781.
DOI: 10.3389/fmed.2023.1238147.
Integration of Lysin into Chitosan Nanoparticles for Improving Bacterial Biofilm Inhibition.
Liu B, Li Z, Guo Q, Guo X, Liu R, Liu X
Appl Biochem Biotechnol. 2023; 196(3):1592-1611.
PMID: 37436548
DOI: 10.1007/s12010-023-04627-2.
Therapeutic potential of phage lysin PlyB in ocular infections.
Mursalin M, Astley R, Coburn P, Bagaruka E, Hunt J, Fischetti V
mSphere. 2023; 8(4):e0004423.
PMID: 37273201
PMC: 10449515.
DOI: 10.1128/msphere.00044-23.
Understanding the Molecular Basis for Homodimer Formation of the Pneumococcal Endolysin Cpl-1.
Alreja A, Linden S, Lee H, Chao K, Herzberg O, Nelson D
ACS Infect Dis. 2023; 9(5):1092-1104.
PMID: 37126660
PMC: 10577085.
DOI: 10.1021/acsinfecdis.2c00627.
The Broad-Spectrum Endolysin LySP2 Improves Chick Survival after Pullorum Infection.
Deng H, Li M, Zhang Q, Gao C, Song Z, Chen C
Viruses. 2023; 15(4).
PMID: 37112818
PMC: 10142873.
DOI: 10.3390/v15040836.
Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.
Liu H, Hu Z, Li M, Yang Y, Lu S, Rao X
J Biomed Sci. 2023; 30(1):29.
PMID: 37101261
PMC: 10131408.
DOI: 10.1186/s12929-023-00919-1.
CBD resistant strains are susceptible to epsilon 34 phage tailspike protein.
Ibrahim I, Ayariga J, Xu J, Adebanjo A, Robertson B, Samuel-Foo M
Front Med (Lausanne). 2023; 10:1075698.
PMID: 36960333
PMC: 10028193.
DOI: 10.3389/fmed.2023.1075698.